Navigation Links
Governor Gray Davis Joins Genesis Biopharma as Chairman of Corporate Advisory Board

LOS ANGELES, May 23, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC.BB:GNBP), a biotechnology company developing targeted cancer therapies, today announced that former California Governor, Gray Davis, has joined the company as Chairman of its Corporate Advisory Board. Governor Davis is committed to the improvement of healthcare and advancement of medical technologies.

During his tenure as governor, California became a leader in stem cell research as well as providing the highest levels of funding in the country for cancer and HIV research and treatment. Governor Davis set the most stringent standards for cancer clinical trials and made history by enrolling more children in the federal children's health insurance program (Healthy Families) than any state previously had.  He is currently Of Counsel at the Los Angeles office of law firm Loeb & Loeb.

"I believe personalized medicine is the future – and holds great promise for those suffering from chronic diseases," stated Governor Davis.

Genesis Biopharma Chairman and CEO, Anthony J. Cataldo, added, "Governor Davis brings tremendous value and insight as a person who has implemented his vision for a better healthcare system through advancements in technology and policy. He offers us his experience in organizational leadership, as well as his knowledge in working with regulatory bodies to help  bring our cancer therapies to market to save lives, reduce healthcare costs, and keep America at the forefront of innovative therapeutics."

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is a development-stage biotechnology company engaged in the development of targeted cancer therapies. For more information about the company, visit

Forward-Looking Statements

The foregoing press announcement contains forward-looking statements that can be identified by such terminology as "expect," "potential," "suggests," "bodes," "may," "should," "could" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the company's ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as of the date they are made. The company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

SOURCE Genesis Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Maryland Governor Martin OMalley to Visit Novavax in Celebration of HHS-BARDA Contract Award
2. Governor OMalley Announces State Grants Available For Maryland Bio Companies
3. Howard J. Leonhardt Announces Candidacy for Governor of California
4. GreenHouse Energy, Governor Schwarzenegger Join in Driving the Future of Fueling in California
5. Venture Capitalists to Invest in Promising PA Life Science Companies, Governor Rendell Says
6. The Biotechnology Industry Organization Honors Georgia Governor Sonny Perdue as Governor of the Year
7. Governor Rendell Says Life Science Industry Will Fuel New Breakthroughs, Generate Jobs for Decades to Come
8. Jack Davis, Diagnostics Industry Executive, Joins the HistoRx Board of Directors
9. Davis Phinney Foundation Launches Exercise-Focused Tools to Help People Live Well With Parkinsons Disease
10. Tengion Appoints A. Brian Davis Chief Financial Officer
11. Davis Phinney Foundation Launches Every Victory Counts Program to Inform and Empower People to Live Well With Parkinsons
Post Your Comments:
(Date:10/12/2017)... CA (PRWEB) , ... October ... ... ( ) has launched Rosalind™, the first-ever genomics analysis platform specifically designed ... bioinformatics complexity. Named in honor of pioneering researcher Rosalind Franklin, who made ...
(Date:10/11/2017)... ... 11, 2017 , ... Proscia Inc ., a data ... titled, “Pathology is going digital. Is your lab ready?” with Dr. Nicolas Cacciabeve, ... and how Proscia improves lab economics and realizes an increase in diagnostic confidence.* ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer ... treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and bind ...
(Date:10/10/2017)... Oct. 10, 2017 International research firm Parks Associates ... speak at the TMA 2017 Annual Meeting , October 11 in ... the residential home security market and how smart safety and security products ... Parks Associates: Smart ... "The residential security market ...
Breaking Biology Technology:
(Date:4/6/2017)... 2017 Forecasts by Product Type ... by End-Use (Transportation & Logistics, Government & Public Sector, ... Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation ... Are you looking for a definitive report on the ... ...
(Date:4/5/2017)... 5, 2017 Today HYPR Corp. , ... server component of the HYPR platform is officially ... end-to-end security architecture that empowers biometric authentication across Fortune ... already secured over 15 million users across the financial ... connected home product suites and physical access represent a ...
(Date:4/4/2017)... --  EyeLock LLC , a leader of iris-based identity ... and Trademark Office (USPTO) has issued U.S. Patent No. ... iris image with a face image acquired in sequence ... th issued patent. "The issuance ... multi-modal biometric capabilities that have recently come to market ...
Breaking Biology News(10 mins):